OVERVIEW

Dihexa (5 mg × 60 Capsules = 300 mg) is a synthetic peptide originally developed and studied in neuroscience research for its potential effects on neuroplasticity, synaptogenesis (formation of new synaptic connections), and cognitive function. Structurally derived from angiotensin IV, Dihexa acts by potentiating the hepatocyte growth factor (HGF)/c-Met signaling pathway, which in experimental models has been shown to promote dendritic spine growth, enhance memory and learning tasks, and support neural connectivity far beyond typical neurotransmitter-modulating nootropics. Some preclinical work suggests it may restore impaired cognitive function in aged or diseased animal models by increasing synaptic density and enhancing neuronal repair processes, making it of interest in studies of Alzheimer’s, stroke recovery, and other neurodegenerative conditions.

Despite this research interest, Dihexa is not approved by the U.S. Food and Drug Administration or any other major regulatory authority for therapeutic or supplement use in humans; it is supplied and marketed strictly for research purposes only and is not intended for ingestion or clinical administration. Human clinical data on its safety, efficacy, or appropriate dosing are extremely limited, and long-term effects are unknown. Because the HGF/c-Met pathway is implicated in cell growth, there are theoretical concerns — including potential oncogenic risk — that make unsupervised use particularly risky outside of controlled research settings. Purity and quality can vary between sources, so individuals should not self-administer Dihexa and should consult qualified healthcare professionals when considering cognitive or neuroprotective therapies.